Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06309914 · ClinicalTrials.gov registry record · NA
The Effects of Mirtoselect®, Virtiva®, and Enovita® on Cognitive Performance and Mood States
A NA study, sponsored by Applied Science & Performance Institute.
- Completed
- Registry status
- NA
- Development phase
- 76
- Enrollment target
NCT06309914: Completed NA study, sponsored by Applied Science & Performance Institute.
NCT06309914 is a NA study that has completed, run by Applied Science & Performance Institute. The registered enrollment target is 76 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06309914, a NA study, has completed, sponsored by Applied Science & Performance Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, 4-week intervention clinical study assessing the efficacy of Mirtoselect®, Virtiva® Plus, and Enovita® on cognitive performance and mood states, and the occurrence of adverse events in response to daily supplementation. The desired sample size for this study is 64 subjects. To account for potential dropouts, we aim to enroll up to 20% over the desired sample size. Therefore, this study will enroll up to 76 healthy men and women (25-55 years of age). Subjects will be randomly divided into four study groups: Placebo, Virtiva® ginkgo biloba extract, Mirtoselect® bilberry extract, or Enovita® grape seed extract. Blocked randomization will be deployed in which subjects are divided into blocks of 4 subjects and each subject within a block is randomly assigned to one of the four study groups.
Primary Outcome
The visual memory test measures how well a subject can recognize, remember, and retrieve geometric figures or spatial representations.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Enovita Grape Seed Extract
- DIETARY_SUPPLEMENT Mirtoselect Bilberry Extract
- DIETARY_SUPPLEMENT Virtiva Plus Ginko Biloba Extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2024-07-08 |
| Phase | NA |
What the finished NCT06309914 record still lists
NCT06309914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT06309914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06309914 about?
NCT06309914 is a clinical study titled "The Effects of Mirtoselect®, Virtiva®, and Enovita® on Cognitive Performance and Mood States". This is a randomized, double-blind, placebo-controlled, 4-week intervention clinical study assessing the efficacy of Mirtoselect®, Virtiva® Plus, and Enovita® on cognitive performance and mood states, and the occurrence of adverse events in response to daily supplementation. The desired sample size ...
What is the current status of trial NCT06309914?
This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2024-02-21. Estimated completion is 2024-07-08.
What interventions are being tested in trial NCT06309914?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Enovita Grape Seed Extract (DIETARY_SUPPLEMENT), Mirtoselect Bilberry Extract (DIETARY_SUPPLEMENT), Virtiva Plus Ginko Biloba Extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06309914?
This trial is sponsored by Applied Science & Performance Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06309914's enrollment target sits among peer trials
76 1062nd of 2000 higher than 932 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI